Inari Medical, Inc. Overview
Pro stress-test →Inari Medical, Inc. is a NASDAQ-listed medical device company focused on treating venous and other vascular diseases through minimally invasive, catheter-based interventions. The company develops purpose-built thrombectomy and revascularization systems including ClotTriever, FlowTriever, InThrill, LimFlow, and VenaCore, targeting large, underserved patient populations in deep vein thrombosis, pulmonary embolism, acute and chronic limb-threatening ischemia, and related conditions.
Strategic Profile
Pro stress-test →Inari competes through specialized, differentiated device design focused on specific procedural workflows rather than broad-platform approaches. The company maintains strong gross margins (88%+) and leverages a growing commercial organization targeting interventional radiologists, cardiologists, and vascular surgeons. Strategic focus centers on clinical evidence generation (PEERLESS study) and geographic/indication expansion to drive adoption and defend against larger competitors entering the space.
Competitive Landscape
Pro stress-test →Inari competes against larger, diversified medical device companies including Stryker (SYK), Boston Scientific, and Penumbra in thrombectomy and vascular intervention markets. While Inari lacks scale and manufacturing breadth, it differentiates through purpose-built, workflow-optimized devices targeting specific indications. Larger competitors are increasingly entering venous thromboembolism space, creating both threat and validation of market opportunity. Inari's smaller sales force and limited geographic footprint present execution risks relative to better-resourced rivals.
Industry Context
Inari Medical, Inc. operates in Venous Thromboembolism (VTE) Thrombectomy Devices.
Key facts
Founded: 2014 · Headquarters: Irvine, California, US · Employees: ~1,200 · Revenue: $605M+ (2023 full year; $153M Q3 2024 run rate) · Market cap: ~$4.5B